National Pharmacy Health & Leadership Alliance Verify a MemberMember Login

What changed today in Metabolic: 2 trial updates

Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.

The signal

NPHLA tracked 2 new official records on this desk today: 2 trial updates.

Why this matters

GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.

What changed

  1. New trial registered: Semaglutide in Alcohol Use Disorder[1]
  2. Trial status changed to “Recruiting”: A Study to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight (VESPER-SUI)[2]
  3. Also reported by Endpoints News: “Lilly starts work on Pennsylvania obesity plant; ITM, AtomVie strike supply deal”.[3]
  4. Also reported by Pharmacy Times: “Speeding Up NSCLC Treatment: AI Scheduling, Subcutaneous Dosing, and Payer Transparency”.[4]

Who this affects

  • Weight-management clinics
  • Med spas
  • Pharmacists
  • Prescribers
  • Medical directors
  • Practice owners & operators

Jurisdictions: Minnesota.

What to watch next

No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.

NPHLA takeaway

These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.

Source file

  1. [1]
    New trial registered: Semaglutide in Alcohol Use Disorder (opens the source in a new tab)

    Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)

  2. [2]
  3. [3]
    Lilly starts work on Pennsylvania obesity plant; ITM, AtomVie strike supply deal (opens the source in a new tab)

    News reportingEndpoints NewsIndustry coverage — headline and link only

  4. [4]
    Speeding Up NSCLC Treatment: AI Scheduling, Subcutaneous Dosing, and Payer Transparency (opens the source in a new tab)

    News reportingPharmacy TimesIndustry coverage — headline and link only

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.